Efficacy studies were performed in U87‐cell‐based subcutaneous tumors, and as per the results, a 23.5% decrease in tumor volume was observed in the mice given iRGD‐modified PLK1‐2‐targeted LHNPs. This evidence concerns the gene PLK1 and neoplasm.